One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.

Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).

Internet Usage by Polish Patients With Multiple Sclerosis: A Multicenter Questionnaire Study.

Background: The internet is a source of knowledge and medium widely used in services that facilitate access to information and networking. Multiple sclerosis (MS) patients find the possibility of acquiring information relating to their condition particularly rewarding.

Objective: We aimed to identify Polish MS patients' preferences by analyzing a percentage of internet users and determining the most common search subjects and patients' approach to information on the internet.

Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.

Introduction: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from their caregivers.

Aim: This study aimed to identify the risk factors for poor adherence to Betaferon® treatment, including early discontinuation and omitting doses.

Materials And Methods: 852 adult patients treated with Betaferon participated in this 24-month study.

Binding of fibronectin to alpha-granule-deficient platelets.

Most of the proposed functions for fibronectin involve its interaction with cells, yet the molecular nature of cellular fibronectin binding site(s) has remained obscure. Thrombin induces saturable platelet binding sites for plasma fibronectin and concurrently stimulates surface expression of a number of platelet alpha-granule constituents including thrombospondin and fibrin which are known to interact with fibronectin. To test the hypothesis that these (or other alpha-granule proteins) mediate plasma fibronectin binding, we used platelets of patients with the Gray Platelet Syndrome.

Antibacterial prophylaxis in patients after prostatectomy.

Seventy-five patients with prostatic adenoma and sterile urine cultures were treated prophylactically after operation, with one of four antibacterial drugs (Nitrofurantoin, Mandelamine, Biseptol, Chlorocid). Administration of Nitrofurantoin and Mandelamine in the postoperative period was found to be advantageous. In patients receiving these drugs, incidence of urinary tract infections was reduced by one half compared with a control group of untreated patients.